These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24132874)

  • 21. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
    Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
    Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
    Jacot W; Bibeau F; Gourgou-Bourgade S; Gutowski M; Colombo PE; Bleuse JP; Kramar A; Romieu G
    Am J Clin Oncol; 2010 Dec; 33(6):544-9. PubMed ID: 20042972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
    O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
    Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
    Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
    Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
    Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
    Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
    Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
    J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant docetaxel for high-risk, node-negative breast cancer.
    Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
    N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
    N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
    Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
    Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
    Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
    Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
    Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
    Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Yamanouchi K; Kuba S; Sakimura C; Morita M; Kanetaka K; Kobayashi K; Takatsuki M; Hayashida N; Eguchi S
    Anticancer Res; 2017 Dec; 37(12):6947-6951. PubMed ID: 29187478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
    J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
    Schneeweiss A; Lauschner I; Ruiz A; Guerrero A; Sánchez-Rovira P; Seguí MA; Goerke K; Wolf M; Manikhas AG; Wacker J; Marmé F; Lichter P; Sinn HP; Sohn C; Mansouri K; Bauknecht T; Hahn M
    Clin Breast Cancer; 2007 Apr; 7(7):555-8. PubMed ID: 17509164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
    Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
    J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.